Monotherapy 100 mg approx every 12 hr until disease progression or unacceptable toxicity. In combination w/ obinutuzumab Patient w/ previously untreated CLL100 mg approx every 12 hr until disease progression or unacceptable toxicity. Start Calquence at cycle 1 (each cycle is 28 days). Start obinutuzumab at cycle 2 for a total of 6 cycles. Administer Calquence prior to obinutuzumab when given on the same day.
Risk of serious infections, including opportunistic infections; serious hemorrhagic events; cytopenias including neutropenia, anemia, thrombocytopenia & lymphopenia; second primary malignancies including skin cancers & other solid tumors; atrial fibrillation or flutter. Avoid administration in patients w/ severe hepatic impairment. May cause fetal harm & dystocia. Advise pregnant women of the potential risk to a fetus. Advise lactating women not to breastfeed while on treatment & for at least 2 wk after final dose. Elderly.
Sign Out
